318 related articles for article (PubMed ID: 27553740)
1. In vitro ceftaroline combinations against meticillin-resistant Staphylococcus aureus.
García AB; Candel FJ; López L; Chiarella F; Viñuela-Prieto JM
J Med Microbiol; 2016 Oct; 65(10):1119-1122. PubMed ID: 27553740
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011.
Sader HS; Flamm RK; Jones RN
Antimicrob Agents Chemother; 2013 Jul; 57(7):3178-81. PubMed ID: 23629712
[TBL] [Abstract][Full Text] [Related]
3. Bactericidal activity of ceftaroline, vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus isolates from cancer patients.
Rolston KVI; Jamal M; Nesher L; Raad I; Rice SA; Rybak MJ; Prince RA
J Glob Antimicrob Resist; 2019 Jun; 17():16-18. PubMed ID: 30844496
[No Abstract] [Full Text] [Related]
4. In vitro activity of fosfomycin alone and in combination against Staphylococcus aureus with reduced susceptibility or resistance to methicillin, vancomycin, daptomycin or linezolid.
Saravolatz LD; Pawlak J
J Antimicrob Chemother; 2022 Dec; 78(1):238-241. PubMed ID: 36374572
[TBL] [Abstract][Full Text] [Related]
5. In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolates.
Vidaillac C; Leonard SN; Rybak MJ
Int J Antimicrob Agents; 2010 Jun; 35(6):527-30. PubMed ID: 20346632
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of ceftaroline in combination with other antimicrobials active against Staphylococcus spp.
Gil Romero Y; Gómez-Garcés JL
Enferm Infecc Microbiol Clin (Engl Ed); 2020 Jan; 38(1):25-27. PubMed ID: 31072712
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of novel anti-MRSA cephalosporins and comparator antimicrobial agents against staphylococci involved in prosthetic joint infections.
Isnard C; Dhalluin A; Malandain D; Bruey Q; Auzou M; Michon J; Giard JC; Guérin F; Cattoir V
J Glob Antimicrob Resist; 2018 Jun; 13():221-225. PubMed ID: 29421316
[TBL] [Abstract][Full Text] [Related]
8. Activity of ceftaroline against extracellular (broth) and intracellular (THP-1 monocytes) forms of methicillin-resistant Staphylococcus aureus: comparison with vancomycin, linezolid and daptomycin.
Mélard A; Garcia LG; Das D; Rozenberg R; Tulkens PM; Van Bambeke F; Lemaire S
J Antimicrob Chemother; 2013 Mar; 68(3):648-58. PubMed ID: 23188792
[TBL] [Abstract][Full Text] [Related]
9. Observed Antagonistic Effect of Linezolid on Daptomycin or Vancomycin Activity against Biofilm-Forming Methicillin-Resistant Staphylococcus aureus in an In Vitro Pharmacodynamic Model.
Luther MK; LaPlante KL
Antimicrob Agents Chemother; 2015 Dec; 59(12):7790-4. PubMed ID: 26369963
[TBL] [Abstract][Full Text] [Related]
10. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
Smith JR; Yim J; Raut A; Rybak MJ
Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic comparison of different antimicrobial regimens against Staphylococcus aureus bloodstream infections with elevated vancomycin minimum inhibitory concentration.
da Costa TM; Cuba GT; Morgado PGM; Nicolau DP; Nouér SA; Dos Santos KRN; Kiffer CRV
BMC Infect Dis; 2020 Jan; 20(1):74. PubMed ID: 31973753
[TBL] [Abstract][Full Text] [Related]
12. Methicillin-resistant Staphylococcus aureus in Stockholm, Sweden: Molecular epidemiology and antimicrobial susceptibilities to ceftaroline, linezolid, mupirocin and vancomycin in 2014.
Fang H; Fröding I; Gian B; Hæggman S; Tollström UB; Ullberg M; Nord CE
J Glob Antimicrob Resist; 2016 Jun; 5():31-5. PubMed ID: 27436463
[TBL] [Abstract][Full Text] [Related]
13. Assessment of invitrosynergy of daptomycin or vancomycin plus ceftaroline for daptomycin non-susceptible Staphylococcus aureus.
Hutton MA; Sundaram A; Perri MB; Zervos MJ; Herc ES
Diagn Microbiol Infect Dis; 2020 Nov; 98(3):115126. PubMed ID: 32861155
[TBL] [Abstract][Full Text] [Related]
14. Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types.
Farrell DJ; Flamm RK; Sader HS; Jones RN
Int J Antimicrob Agents; 2014 Apr; 43(4):323-7. PubMed ID: 24411474
[TBL] [Abstract][Full Text] [Related]
15. Vancomycin plus ceftaroline shows potent in vitro synergy and was successfully utilized to clear persistent daptomycin-non-susceptible MRSA bacteraemia.
Barber KE; Rybak MJ; Sakoulas G
J Antimicrob Chemother; 2015 Jan; 70(1):311-3. PubMed ID: 25125677
[No Abstract] [Full Text] [Related]
16. Rates of killing of methicillin-resistant Staphylococcus aureus by ceftaroline, daptomycin, and telavancin compared to that of vancomycin.
Marconescu P; Graviss EA; Musher DM
Scand J Infect Dis; 2012 Aug; 44(8):620-2. PubMed ID: 22668202
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the synergistic effect of ceftaroline against methicillin-resistant Staphylococcus aureus.
Tsai CE; Yang CJ; Chuang YC; Wang JT; Sheng WH; Chen YC; Chang SC
Int J Infect Dis; 2022 Sep; 122():230-236. PubMed ID: 35640827
[TBL] [Abstract][Full Text] [Related]
18. Bacteremia due to Methicillin-Resistant Staphylococcus aureus: An Update on New Therapeutic Approaches.
Holubar M; Meng L; Alegria W; Deresinski S
Infect Dis Clin North Am; 2020 Dec; 34(4):849-861. PubMed ID: 33011050
[TBL] [Abstract][Full Text] [Related]
19. Activity of Different Antistaphylococcal Therapies, Alone or Combined, in a Rat Model of Methicillin-Resistant Staphylococcus epidermidis Osteitis without Implant.
Albac S; Labrousse D; Hayez D; Anzala N; Bonnot D; Chavanet P; Aslangul E; Croisier D
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31740562
[TBL] [Abstract][Full Text] [Related]
20. Dalbavancin Alone and in Combination with Ceftaroline against Four Different Phenotypes of
Kebriaei R; Rice SA; Stamper KC; Rybak MJ
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
